In April 2026, Startale closed a $63 million Series A — the largest single round tracked across femtech in the month — positioning the company as a blockchain-plus-health-tech cross-sector player backed by financial giants SBI Group and Sony. The round is notable both for its size (roughly double Chexy's $30M Series A earlier in the same month) and for a thesis rarely seen in women's health funding: integrating on-chain identity and data ownership with traditional finance rails for patient-held health records.

Why It Matters

If Startale executes, it would be the first major femtech to put user-owned health-data sovereignty at the center of its product — a contrast to the ad-supported and data-monetized incumbents. The $63M round is also a signal that the femtech funding drought which forced Elvie into administration in 2025 has broken: two $30M+ rounds in the same month, plus UK government co-investment, suggest the sector is back on the offense after the Q1 2026 $1.24B total. Whether blockchain is actually the right substrate for that sovereignty story — or whether it's a distraction — is the open question.

The raise lands during a broader surge: mean.ceo's April 2026 femtech roundup logs record month-over-month activity, UK Health Secretary Wes Streeting on April 15 announced a £1.5M FemTech Challenge Fund inside the renewed Women's Health Strategy, and April deal flow also included IdentifyHer's Peri perimenopause wearable and myStoria's $1.625M seed for reproductive-health care coordination. Collectively, Q1 2026 women's health investment was tracked at roughly $1.24B — a pace that puts 2026 on track to exceed any prior year.

Startale's positioning is the strategic wildcard. Traditional femtech raises have gone to DTC hardware (Elvie, Willow), fertility apps (Flo, Clue), or telehealth (Tia, Maven Clinic). Startale's pitch — crossing blockchain infrastructure into women's health-data sovereignty — reads as a direct response to two 2025–2026 stressors: the post-Dobbs data-privacy panic around period tracking in the U.S. (prompting state-level data laws in California, Washington, and Connecticut), and the broader femtech privacy critique that Royal Holloway's March 2026 menopause-app study sharpened with its finding that 69% of UK users feel underserved yet have little control over their intimate data.

SBI Group's backing signals Japanese financial-services interest in the space; Sony's participation is more unusual and hints at consumer-electronics integration possibilities (Sony's biometric-sensor IP, their AI division's language-model work). The company has not publicly disclosed clinical partnerships or go-to-market timing, but the raise puts it in the top tier of 2026 femtech companies by capitalization.

Sources

Update — 2026-04-19

Initial entry — story first created.